Development of Targeted Gene Delivery Systems for Lung Cancer Therapy
The development of targeted gene delivery systems has become a pivotal focus in lung cancer research, aiming to improve the specificity and efficiency of therapeutic nucleic acid delivery while minimizing off-target effects and toxicity. Lung cancer presents unique challenges for gene delivery due to the complex architecture of lung tissue, the presence of mucus barriers, and the heterogeneity of tumor cells.
One promising approach involves engineering nanoparticle carriers that can selectively recognize and bind to surface markers overexpressed on lung cancer cells, such as EGFR, integrins, or folate receptors. These targeted delivery vehicles—ranging from liposomes and lipid nanoparticles to polymeric and inorganic nanocarriers—enhance cellular uptake via receptor-mediated endocytosis, increasing intracellular delivery of therapeutic genes or RNA molecules.
Optimization of the carrier composition is essential to balance stability in circulation with efficient release of genetic cargo inside target cells. Surface modification with polyethylene glycol (PEG) improves circulation time by reducing clearance by the immune system, while cleavable linkers enable cargo release in response to tumor-specific stimuli such as pH or enzymatic activity.
In addition to ligand-targeted systems, inhalation delivery methods are being explored to deposit gene therapeutics directly into the lungs, bypassing systemic barriers and reducing systemic toxicity. Aerosolized nanoparticles must overcome mucociliary clearance and penetrate the mucus layer to reach tumor cells effectively.
Combining targeted delivery with advanced gene editing or silencing technologies, such as CRISPR/Cas9 or siRNA, enables precise modulation of oncogenes and resistance pathways in lung cancer. Preclinical studies demonstrate improved therapeutic outcomes with reduced off-target gene expression, highlighting the potential of targeted gene delivery to transform lung cancer treatment.
Despite significant progress, challenges remain in scaling up production, ensuring reproducibility, and addressing immune responses. Continued research into delivery mechanisms, tumor biology, and material science will drive the translation of targeted gene delivery systems into clinical lung cancer therapies.
References: Altogen.com Altogenlabs.com